"In 2024, Kenmare delivered EBITDA of $157 million, supporting our ability to fund our capital programme and continue to make shareholder distributions. As such, the Board is proposing a full year ...

BOSTON, March 25, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today reported financial results ...